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ABSTRACT
Lyme borreliosis (LB) is the most prevalent
arthropod-borne infectious disease in North
America and many countries of the temperate
Northern Hemisphere. It is associated with local
and systemic manifestations and has persistent
post-treatment health complications in some
individuals. Innate and acquired
immunity-related inflammation is likely to
play a critical role in both host defense against
Borrelia burgdorferi and disease severity.
Large-scale analytical approaches to quantify
gene expression (transcriptomics), proteins
(proteomics) and metabolites (metabolomics)
in LB have recently emerged with a potential to
advance the development of disease biomarkers
in early, disseminated and posttreatment
disease stages. These technologies may permit
defining the disease stage and facilitate its early
detection to improve diagnosis. They will also
likely allow elucidating the underlying
molecular pathways to aid in identifying
molecular targets for therapy. This article
reviews the findings within the field of omics
relevant to LB and its prospective utility in
developing an array of biomarkers that can be
employed in LB diagnosis and detection
particularly at the early disease stages.
Keywords: Biomarkers; Omics; Diagnosis;
Inflammation; Innate immunity; Lyme disease
INTRODUCTION
Lyme disease—also known as Lyme borreliosis
(LB)—can be caused in humans by at least three
genospecies of the Borrelia burgdorferi sensu lato
complex, B. burgdorferi, B. garinii and B. afzelii.
In the USA and southern Canada, B. burgdorferi
sensu stricto cause flu-like illness at early disease
stages that can later develop to Lyme arthritis
and other long-term complications [1]. LB is
Enhanced content To view enhanced content for this
article go to http://www.medengine.com/Redeem/
5327F06058F9862F.
A. Badawi (&)
Public Health Risk Sciences Division, Public Health




Department of Nutritional Sciences, Faculty of
Medicine, University of Toronto, FitzGerald
Building, 150 College Street, Toronto, ON, Canada
Infect Dis Ther (2017) 6:85–102
DOI 10.1007/s40121-016-0138-6
initiated by the bacterial infection following a
bite from an infected Ixodes scapularis or Ixodes
pacificus blacklegged tick. Presently, LB is the
most common vector-borne disease in North
America and Europe [1]. Over 30,000 cases are
reported in the US annually [2]. However, actual
prevalence estimates are thought to be at least
ten times as high because of underreporting [3].
In Canada, an increased incidence of LB by
*six-fold—from 128 to 707 cases—was noted
between 2009 and 2015 [4].
Symptoms of early LB (stage 1) usually begin
1–2 weeks after a tick bite with a proportion of
patients developing the characteristic erythema
migrans (EM) rash that can last 4 weeks or
longer and may be accompanied by fatigue,
malaise, fever, chills, myalgia and headache. If
untreated, bacteria may then disseminate
systemically via the lymphatic system or blood
to the joints, nervous system and cardiovascular
system. Symptoms of early disseminated LB
(stage 2) may occur weeks to months after the
tick bite and may include numbness, Bell’s
palsy, palpitations, chest pain or shortness of
breath. Approximately 6 months after
infection, patients may present with joint pain
and swelling, and synovial fluid findings that
suggest an inflammatory process. Months to
years after the initial tick bite, LB can progress
to the late disseminated stage (stage 3), which
may result in substantial morbidity, primarily
from chronic arthritis. Indeed, arthritis usually
manifests during the late disease stage and
occurs in up to 60% of untreated patients.
Neurologic and cardiac involvements have been
also described. Cardiac involvement usually
occurs within 1 to 2 months after infection
with Lyme carditis as a less common
complication of the systemic LB disease [for
review, see Ref. 5]. As the innate and adaptive
immune responses develop following the
infection, patients may recover during the
early disease phase without antibiotic therapy.
LB patients treated with antibiotics in the early
stages do not develop detectable antibodies
[6, 7]. Most patients who are not treated in
early LB go on to suffer early disseminated LB
with manifestation of neuroborreliosis (e.g.,
Bell’s palsy and meningitis), multiple EM
lesions and, less commonly, myocarditis
[8–10]. These stages and characteristics are
based on the guidelines developed by the
Infectious Diseases Society of America (IDSA)
[9]. The IDSA LB guidelines have been delisted
recently by the US National Guideline
Clearinghouse (NGC) as they do not conform
to the Grading of Recommendations
Assessment, Development and Evaluation
(GRADE) methodology endorsed by the
Institute of Medicine (IOM). The presently
listed LB guidelines by NGC are those of the
International Lyme and Associated Diseases
Society (ILADS) guidelines [11].
Inflammation, induced by either the
spirochete or its antigens in the affected
tissues, is thought to play a major role in LB
pathogenesis at both the early and late disease
stages [12, 13]. Early inflammatory responses
distinguish patients from healthy controls and
diverge from those of other diseases with
overlapping clinical features [12]. The final
outcome of infection, however, is dependent
on the intricate interaction between the
pathogen and the host immune response
[12, 13]. Therefore, elucidating the extent of
alteration in the host inflammatory and
immunological pathways at the early stages of
host-pathogen interaction may provide an
insight into the potential mechanisms
rendering B. burgdorferi-infected subjects
susceptible to disseminated LB and, perhaps,
the later development of post-treatment Lyme
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disease syndrome (PTLDS). It may also facilitate
characterizing an array of biomarkers for
various disease stages that can serve as targets
for new diagnostic techniques and assist in
development of therapies [13].
Early LB is usually diagnosed by the
recognition of an EM skin lesion as
detectable antibodies are not present at the
very early disease stage in many patients [14].
However, other skin lesions can be confused
with EM, e.g., southern tick-associated rash
illness, tick-bite hypersensitivity reactions and
some cutaneous fungal infections [6, 15, 16].
Several laboratory-based molecular and
immunologic approaches for detection of B.
burgdorferi sensu lato and diagnosis of LB have
been developed over the past 3 decades [17].
These included tests for direct detection of the
spirochete, the detection of specific antibodies
using whole-cell lysates, recombinant antigens
or peptide antigens in enzyme immunoassays
(EIA), or nucleic acid amplification from
peripheral blood samples [for review, see 17].
At early disease stages, detection of B. burgdorferi
antibodies or using PCR-based approaches in
peripheral blood samples were proved
unsatisfactory [17]. Currently, an
antibody-based diagnostic method is widely
utilized in clinical practice, and a two-tier
approach for serologic testing—using EIA
followed by immunoblotting for IgM and
IgG—is recommended [18]. The approach is
based on antibody detection and is highly
specific and sensitive in patients with late
manifestations of LB but exhibits a moderate
sensitivity (29%–40%) in those in early disease
[14, 17]. Recent evidence, however, suggests
that serological testing can be poor, even in LB
patients who were culture-positive for B.
burgdorferi [19]. The current status of LB
serological testing emphasizes the need for
more sophisticated approaches such as omics
technologies at all disease stages.
These limitations, together with the possible
misdiagnosis of EM lesions by clinicians,
necessitate the development of an improved
test for the detection of LB, particularly at the
early disease stages. Non-antibody-based
methodologies have been proposed as a novel
approach for the detection of spirochetes or
assessing the responses to the pathogen [17]. If
these methods improve the established
diagnostic tests by having higher specificity
and sensitivity, they will enhance patient
management and may obviate repeated testing
and help alleviate controversies and
subjectivities over LB diagnosis [14].
Driven by marked improvement in analytical
platforms, increasing resolution and sensitivity,
high-throughput capabilities and reduced cost,
the use of omics approaches has grown
exponentially in recent years [20]. Omics
methodologies have allowed elucidating
mechanisms of pathogenesis for numerous
disease-causing agents and facilitated discovery
of disease biomarkers (biosignature) and
response to prevention or therapy [20–24]. It
has the potential to assess the effects of a
particular factor on many molecules including
thousands of mRNAs, proteins, metabolites,
imprinting of genes, alternative splicing of
mRNAs and mutations [22]. The present article
provides a comprehensive evaluation and
review of the omics technologies employed to
study biomarkers and biosignatures of early LB
stages in human. The contributions of the
individual omics analytical platform to
understanding disease etiology is presented,
with a goal to provide a background on their
respective abilities in identifying a panel of
inflammatory mediators as biomarkers for early
disease detection and diagnosis.
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Inflammation in the Early Stages of Lyme
Disease
Following exposure to foreign microbial,
chemical or physical agents, the first line of
host defense is the activation of the innate
immune response, which results in
inflammatory reactions to mediate damage
repair, isolate or eliminate the infectious factor
and re-establish homeostasis [25, 26]. The
initiation of innate immunity-related
inflammatory reactions relies on the pattern
recognition receptors (PRRs) such as the
Toll-like receptors (TLRs). TLRs are type I
transmembrane proteins that have an
extracellular domain containing leucine-rich
repeats (LRRs) and a cytoplasmic tail with a
conserved Toll/interleukin-1 (IL-1) receptor
(TIR) domain [27]. Additional pathogen
recognition occurs by nucleotide
oligomerization domain (NOD)-like receptors
(NLRs) and C-type lectin (CTL) receptors (CLR).
TLRs recognize structurally conserved
pathogen-associated molecular patterns
(PAMPs) [28–30] and trigger a downstream
signaling cascade that activates the
transcription factor NF-jB. Activation of NF-jB
elicits stimulation of cytokine synthesis,
upregulation of adhesion molecule expression
and generation of reactive oxygen species
[30–33].
Proinflammatory cytokines, such as TNF-a,
IL-6, IL-8 and IL-1b, are produced
predominantly by activated macrophages and
are involved in the upregulation of
inflammatory reactions. Early stages of LB
infection are linked to the synthesis of several
of these monocyte-derived cytokines that play a
critical role in disease pathogenesis [34–38, see
below]. Proinflammatory cytokines activate
phagocytes to recognize and eliminate
pathogens and facilitate attracting other
immune cells to the site of infection.
Furthermore, these cytokines induce T cell
polarization leading to production of IFN-c by
Th1 lymphocytes and IL-17 by Th17 cells [39].
During early B. burgdorferi infection, IL-1b is
produced in high concentrations by
monocytes/macrophages [40–42], a synthesis
that is triggered primarily by the
peptidoglycan molecules of the bacterial cell
wall [43]. Levels of IL-1b were higher in synovial
fluid and tissue of patients with post-treatment
Lyme arthritis compared to their counterparts
who recovered after the antibiotic treatment
[42]. Although the role of IL-1b is yet to be fully
understood and is controversial—together with
other cytokines—at post infection and PTLDS
[11], it was thought to be related to the
induction of a IL-17/Th17 response against the
spirochetes and the subsequent synthesis of
IL-22 [40]. Thus, IL-17/Th17 response augments
the immune activation upon microbial
recognition [40] with IL-1b controlling the
production of IL-17A, IL-17F, IL-17AF, IL-21,
IL-22 and IL-26. These products of Th17,
particularly IL-22, are critical factors in the
development of the Borrelia antigen-induced
arthritis in animal models [44, 45]. IL-1b
blockade was, therefore, associated with a
disrupted Th17 response and IL-17 levels [35].
IL-22 (and IFN-c) was detected in the skin of
individuals with EM [46], and IL-17 was found
in higher levels in synovial cells from Lyme
arthritis patients [47] and patients with
neuroborreliosis [48] than subjects with earlier
disease stages.
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Antiinflammatory cytokines are
immunoregulatory molecules that control the
response to proinflammatory cytokines and
play a critical physiologic role in the systemic
inflammatory states. Major antiinflammatory
cytokines include IL-1 receptor antagonist
(IL-1Ra), IL-4, IL-5, IL-10, IL-11 and IL-13.
Several studies from human and animal
models demonstrated that Th2 (synthesis of
the antiinflammatory IL-4, -5, -10 and -13) is
more predominant than Th1 within the target
organ following the exposure to Borrelia
[38, 40, 49]. Indeed, human monocytes
exposed to B. burgdorferi outer surface protein
A (OspA) and the intact spirochetes synthesized
high levels of IL-10 [50], which, in turn,
inhibited the function of monocytes,
macrophages and Th1 cells and reduced their
migration through endothelial cells [51]. IL-12
and IL-18, which are secreted by
antigen-presenting cells (APCs) to induce Th1,
were also elevated in cerebrospinal fluid from
patients with neuroborreliosis [52]. Studies in
Borrelia-infected mice [53] and patients with
neuroborreliosis [54] have shown that a rapid
IFN-c response provides a more beneficial
outcome than a slower or no responses.
However, this instantaneous response was
associated with a subsequent IL-4 production
[53, 54], indicating that a Th1 response,
although critical for spirochetal eradication,
can consequently contribute to tissue damage
and persistent inflammation if unregulated.
Interaction of TLRs with B. burgdorferi Osps is
critical in early stages of LB pathogenesis
[1, 36, 55, 56] and was thought to mediate
both short- and long-term disease outcomes
[57–59]. A number of single-nucleotide
polymorphisms (SNPs) in the TLR genes [13]
and their downstream factors [60, 61] were
recently proposed to modulate the host
response to infection. These SNPs alter the TLR
signaling patterns and may have an impact on
the clinical manifestations of bacterial, fungal
and viral infections [62]. For example, TLR1
Ile602Ser was linked to elevated
proinflammatory cytokine levels and a more
effective Th1-like response (i.e., the
microbicidal action of IFN-c) in LB patients
[63] at early disease stages. TLR2 Arg753Gln
polymorphism, however, provided protection
against the development of late disease stage
[64]. PBMCs with TLR1 Arg80Thr, Asn248Ser,
and Ile602Ser and TLR6 Ser249Pro had a
significantly lower synthesis of
proinflammatory cytokines compared to their
wild-type counterparts [65].
TLR1 T1805G (Ile602Ser), TLR2 G2258A
(Arg753Gln) and TLR5 C1174T (Arg395Stop)
were examined in patients with different LB
symptoms including EM and
antibiotic-responsive and refractory arthritis
[63]. These SNPs were associated with
decreasing numbers of plasma membrane TLRs
(TLR1 T1805G and TLR2 G2258A) or with
abrogation of the cellular flagellin signaling
pathway (TLR5 C1174T) leading to an overall
impairment of the TLR pathway and a disrupted
state of cytokine synthesis [63]. Patients with
antibiotic-refractory arthritis had *two-fold
higher frequency of TLR1 Ile602Ser (T1805G)
compared to those with EM (OR = 1.9; p = 0.05)
[63]. This status of antibiotic-refractory Lyme
arthritis occurs when there is persistence of
synovitis for at least 3 months after antibiotic
treatment, despite expulsion of viable B.
burgdorferi from the affected area [65].
Similarly, SNPs in TLR8 were proposed to lead
to immunodeficiency syndromes and may be
associated with an increased risk of severe
clinical manifestations following B. burgdorferi
infection [66, 67]. In contrast to the increased
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risk of Lyme arthritis associated with TLR1
Ile602Ser (T1805G), TLR2 Arg293Gln (A2258G)
was shown to be protective [64]. One study
demonstrated that the frequency of TLR2
Arg753Gln (A2258G) is lower in LB patients
compared to matched controls (OR = 0.39,
p = 0.03). In this study, patients with stage 3
LB (i.e., late persistent Lyme arthritis) had a
further lower frequency of Arg753Gln (A2258G)
compared to the matched controls (OR = 0.15,
p = 0.003), suggesting a protective effect of
TLR2 Arg293Gln in Lyme arthritis [64]. Other
TLR gene polymorphisms such as TLR5
(Arg395Stop) and TLR6 (Ser249Pro) were
identified to have a functional significance in
host-pathogen interaction during both early
and late LB stages [13, 63, 64, 68].
In general, after initial recognition of
Borrelia by TLR2/TLR1 heterodimers, the first
stage in the innate immunity-related
inflammation is phagocytosis. This leads to a
robust proinflammatory cytokine synthesis.
TLRs, known to recognize nucleic acids (e.g.,
TLR7, 8 and 9), might also recognize Borrelia
RNA or DNA. This would result in the
production of a type I IFN signature, a process
to which NLRs may contribute [39]. Production
of various cytokines critical to the pathogenesis
of LB, e.g., IL-1b, IFN-c and IL-17, is
subsequently induced. In particular, IL-1b was
demonstrated to be associated with the acute
and chronic inflammatory processes seen in LB
[39].
Omics Biosignature in the Early Stages
of Lyme Disease
Omics technologies permit examining the
differences in DNA, RNA, proteins, metabolites
and other molecules between and among
species. These molecular profiles may vary
with cell or tissue exposure to chemicals, drugs
or pathological agents and thus have potential
use in elucidating disease etiology, detection
and potential preventive approaches. Omics
assessments are often conducted in a
high-throughput manner to produce large data
sets on functional, structural and/or
response-related alterations within a particular
body compartment, e.g., cell, tissue or fluid. As
previously stated, ‘‘these new methods have
already facilitated significant advances in our
understanding of the molecular responses to
cell and tissue damage, and of perturbations in
functional cellular systems’’ [69]. Furthermore,
the integrated approach implemented in omics
can enable a comprehensive delineation of the
genetic control to cellular functions and
responses to alterations.
The contributions of an individual omics
platform to recognizing LB etiology and the
potential of these techniques in identifying a
panel of biomarkers for early disease detection
and diagnosis present distinct challenges given
the paucity of existing information. For
example, in humans, no genome-wide
association study has been conducted yet on
LB with a small number of reports existing on
other omics techniques. Highlighted below is,
therefore, the available information from
transcriptomics, metabolomics and
inflammatomics studies specifically at the
early disease stages.
Transcriptomics in Lyme Disease Patients
Transcriptomic analysis aims to describe and
quantify RNA species such as mRNAs,
non-coding RNAs and small RNAs and their
variations in response to external stimuli or
disease. Expression profiling by microarrays has
been widely used to detect variations in the
expression of many, but not all, transcribed
genes under both normal and perturbed
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conditions. In an attempt to gain insights into
the molecular basis of acute LB and the ensuing
development of post-treatment symptoms, a
recent longitudinal transcriptome study was
conducted on LB patients enrolled at the time
of diagnosis and followed at 3 weeks and
6 months post-antibiotic treatment [70]. At the
time of diagnosis, the transcriptomes of LB
patients revealed a total of 1235 differentially
expressed genes compared to the matched
controls. Among those, the expression of 37
genes was up- or downregulated above the
significant threshold of two-fold. Three weeks
following the completion of a standard course
antibiotic treatment, 1060 genes were
differentially expressed with only 17 above the
2-fold threshold [70].
The differentially expressed genes at both
the time of diagnosis (panel I, Fig. 1) and at 3
weeks following the completion of treatment
(panel II, Fig. 1) were found to influence *80
different pathways, the majority of which were
linked to the innate immunity-related
inflammation (Fig. 1). Analysis of the
pathways modulated by these differentially
expressed genes revealed activation of the
inflammatory response, immune cell
trafficking and hematologic system pathways.
Of the ten most altered pathways, eight were
directly related to the host immune response.
Specifically, the eukaryotic initiation factor 2
(eIF2) signaling pathway was downregulated at
diagnosis. eIF2 signaling plays a central role in
modulating translation initiation and protein
synthesis and elongation in response to cellular
stress [71]. Functional disruption and
downregulation of the eIF2 pathway was
noted with a number of intracellular bacterial
pathogens [72]. However, Borrelia spirochetes
do not enter cells during infection or express
eIF2 inhibitors [73]. Conversely, some evidence
demonstrates that B. burgdorferi can invade
various cell types in vitro [74]. Therefore, it is
not known whether the downregulation of the
eIF2 pathway in LB patients is caused by
Borrelia-mediated immune dysregulation or is
simply a host response to limit tissue injury
[70]. Further studies are needed to assess
whether eIF2 inhibitors may be potential
targets for inflammatory responses in LB as
proposed previously for other pathological
disorders [72].
Transcriptional upregulation was prominent
in TLR1, TLR2, TLR4, TLR7 and TLR8 during the
early stages of LB, i.e., at diagnosis [70] together
with a lack of activation of the inflammatory T
cell apoptotic and B-cell developmental
pathways [70]. This broad upregulation of the
TLRs reflects a general increase in their
regulatory activity rather than a direct
association with B. burgdorferi proteins. In this
respect, the most critical upstream regulators in
LB at early stages were the proinflammatory
(IFN-c, IL-1b, and TNF-a) and antiinflammatory
(IL-6, IL-10) cytokines together with NF-jB and
the immunoglobulin complex [70]. TNF-a was
the common upstream regulator of the
TLR-signaling and the TREM1 (triggering
receptor expressed on myeloid cells-1)
pathway, an amplifier of the immune and
inflammatory response [75]. Modulation of
TREM1 impacts a number of inflammatory
conditions, including septic shock and acute
dengue virus infection [25, 26]. It is worth
noting that only MIAT (myocardial
infarction-associated transcript), CCDC163P
(coiled-coil domain containing 163,
pseudogene), ZNF266 (zinc finger protein 266)
and GPR15 (G-protein coupled receptor 15)
were found to be differentially expressed in
patients with persistent LB symptoms compared
to those with resolved disease [70].
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Transcriptomics in Macrophages
The transcriptomic findings in LB patients are
supported by earlier studies from mouse J774
macrophages stimulated with live B. burgdorferi
spirochetes [76]. Transcriptome profiling in
these cells revealed that spirochetes had
significantly upregulated the expression of 347
gene transcripts and downregulated *700
others (with over a two-fold change). Among
these genes, B. burgdorferi specifically altered the
expression of an array of innate immunity- and
inflammation-related genes to trigger the
production of inflammatory mediators via
recognition of TLRs (Fig. 2). Some of these
genes include chemokine (C-X-C motif) ligand
genes (e.g., Cxcl2 and Cxcl10), genes that
encode monocyte-derived chemokines (e.g.,
Fig. 1 Heat map of pathways modiﬁed at the early stages
of Lyme disease [70]. Pathways found to be up- or
downregulated at Lyme disease diagnosis (stage I) and
3 weeks post-treatment with a standard course of
antibiotics (stage II). Levels of change and the
corresponding color scheme were extrapolated from the
reported z-scores. Based on the level of change (z-scores) of
stage I, the 78 modulated pathways were rearranged into
four categories: z-score = -5.0 to 0.5 (panel a), 0.5–1.5
(panel b), 1.5–2.5 (panel c) and 2.5–5.0 (panel d). Data
were inferred from the supplementary materials of the
original study [70]
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Ccl2, Ccl5 and Ccl9), proinflammatory cytokine
genes (e.g., Tnf and ILs) and TLR genes (TLR1
and TLR2) [66, 76, 85, 86]. Induction of
effectors of the adaptive immune system, such
as CD40 and CD86, which drive T-cell
activation and proliferation, was also
prominent [77] as well as IFN-a/
IFN-ß-inducible genes and a number of
downstream factors including NFjB and
interleukins [76]. Overall, the transcriptomic
biosignature of the differentially expressed
genes and pathways was persistent during
early stages of LB infection [70, 76]. This
observation was demonstrated both in vivo
[70] and in vitro [76], suggesting that a clinical
diagnostic test for LB based on host gene
expression can be a feasible approach for
diagnosis of early disease stages. Furthermore,
this approach can be employed during the
period between infection and appearance of
detectable antibody, a time window of a current
diagnostic gap and subjectivity of clinical-based
diagnosis [14, 17].
Metabolomics in Lyme Disease Patients
Metabolomics is the analysis of the whole
metabolome (low molecular weight
molecules) under a given set of physiological,
environmental and/or clinical conditions
[20, 21, 78]. To develop a metabolic
biosignature that identifies LB patients at
early disease stages and classifies them from
non-patients, serum samples from patients and
healthy controls were recently analyzed for
small molecule metabolites [14]. The
generation of a metabolic biosignature was
based on the hypothesis that the
inflammatory responses at the early disease
stage is distinguished from that in healthy
controls and of other conditions with similar
clinical features [14]. Together with statistical
Fig. 2 Differentially expressed gene transcripts in response
to B. burgdorferi [76]. The selected ones are the top 50
downregulated (upper panel) or upregulated (lower panel)
gene transcripts. Genes were considered to be differentially
expressed when exhibiting C2-fold change, compared with
unstimulated cells. Mouse macrophages were treated with
live B. burgdorferi for 4 h. Data were extrapolated from the
supplementary materials of the original study [76]
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modeling, proteomic analysis allowed for the
initial chemical identification of 95 molecular
features that resulted in 49 assigned putative
chemical structures (Fig. 3). The identified
metabolites included: 11 polyunsaturated
fatty acids (PUFAs) or lipids with PUFAs, and
related to these, 6 products of prostaglandin
metabolism; 8 structures of fatty acid or
cholesterol metabolism; sphingolipids;
plasmalogens; products of tryptophan, purine
and heme metabolism; an endogenous alkaloid
and 7 peptides. This metabolic biosignature
permitted distinguishing early LB patients from
healthy controls with a sensitivity of 88% and
a specificity of 95%. In this study, sera were
collected from early LD patients and healthy
controls. Other disease sera were also collected
for metabolic biosignature comparison with LB
from patients with infectious mononucleosis,
fibromyalgia, severe periodontitis and syphilis.
The study revealed a shift in the abundance of
selected metabolites in patients with early LD
as compared to healthy controls and patients
diagnosed with other diseases [14]. The
majority of the putatively identified
metabolites in the early LB biosignature were
lipid or lipophilic structures, suggesting that B.
burgdorferi infection elicits alterations in
markers of the inflammatory response as well
as lipid mediators [14]. This inflammatory
pathway is, however, related to prostaglandin
synthesis and cyclooxygenase cascades [14]
rather than innate immune-associated
inflammation (Fig. 3). Since the host
inflammatory responses initiated by B.
burgdorferi lead to the clinical manifestations
of this disease [79], the observed metabolic
profile was proposed to reflect a host response
that emerges rapidly following infection. In
support, innate immunity-related
inflammatory markers were significantly
increased in LB patients at the pre-treatment
stage compared to healthy controls with no
inflammatory conditions and changes were
associated with greater rates of lymphopenia,
elevated liver enzymes and a higher number of
disease symptoms although they had higher
rates of seroconversion [12].
The findings of the differentially expressed
genes and pathways identified by
transcriptomics in LB patients [70] (Fig. 1)
were consistent with those described in vitro
in mouse macrophage cells [76] (Fig. 2) and
were further validated by the outcome of a
number of metabolic analyses in both human
and cell culture models [12, 14, 76, 80]. In
Fig. 3 Molecular features assigned putative chemical
structures for the metabolic biosignature of Lyme disease
[14]. The molecular features were assigned according to
the number of chemical pathways related to each
molecular feature. Data were extrapolated from the
supplementary materials of the original study [14]
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mouse J774 macrophages stimulated with live
B. burgdorferi, the inflammatory marker mRNA
gene transcripts induced by spirochetes were
examined at the protein level [76].
Genotype-phenotype matching was observed
in these cells, as the 18 cytokines/chemokines
that exhibited mRNA transcript upregulation
resulted in increased levels of IL-1a, IL-1b,
IFN-c, CCL5 and IL-9 in stimulated
macrophages compared to the unstimulated
cells [76]. Furthermore, early response to live
Borrelia spirochetes was examined in whole
blood cells from 21 patients with different
clinical outcomes of LB [80]. In asymptomatic
seropositive LB affected subjects, an increased
numbers of TNF-a-secreting dendritic cells and
elevated levels of IL-12 were observed compared
to seronegative controls or patients with PTLDS.
The proinflammatory and antibacterial TNF-a
and IL-12 are capable of inducing Th1 responses
[81, 82], and their secretion in asymptomatic
subjects supports their role in the early
resolution of LB conditions. Other innate
cytokines (e.g., IL-1b, IL-6, IL-8, IL-10) were
also detectable early in Borrelia-stimulated
whole blood cells [80]. It can be suggested,
therefore, that the levels of serum chemokines
and the expression of their respective genes may
be informative biomarkers for early stages of LB
that can also relate to specific disease
manifestations.
Inflammatomics in Lyme Disease Patients
A recent study evaluated the levels of 58
immune mediators and 7 acute phase markers
from sera of patients diagnosed with acute LB
and matched controls [12]. Elevated levels of
monocyte-derived chemokines (CCL19,
CXCL9, CXCL10), acute phase inflammatory
reactants such as CRP and serum amyloid A
(SAA), several IL-1 cytokine family members
(IL-1Ra, IL-18, IL-33), inflammatory cytokines
(TNF-a and IL-6) and the T cell cytokine IL-2
were observed in patients with acute LB. In that
study, the levels of CXCL9 and CXCL10 were
coordinately increased in the LB patients,
particularly in a subgroup displaying an
overall elevated level of inflammatory markers
(see below), and was associated with induced
liver enzymes [12]. It is known that EM lesions,
the primary site of inflammation and bacterial
replication in early LB, express high levels of
CXCL9 and CXCL10 [46, 83]. Taken together,
this observation and the association between
CXCL9/CXCL10 levels and lymphopenia both
indicate that the infection-induced tissue
inflammation and chemokine production
stimulate the recruitment of activated effector
T cells from the blood into the site of infection
[12].
Close inspection of these findings indicated
that a higher percentage of LB patients was
found to have concentrations of inflammatory
markers above the average levels compared to
healthy controls (Fig. 4). On the other hand, an
increased percentage of healthy subjects were
noted to have levels of inflammatory markers
below the average values compared to LB
patients (Fig. 4). Patients with acute LB also
exhibited upregulation of acute phase reactants
such as CRP and SAA. CRP is a short pentraxin
that acts as a fluid phase pattern recognition
protein [84] whereas SAA is a serum lipoprotein
that recognizes bacteria by interacting with the
Osps [85]. Infection with B. burgdorferi
apparently stimulates the coordinated
production of CRP and SAA along with IL-6
[86, 87] and elevated serum liver enzymes
during the acute stage of LB [12]. Other
changes in cellular markers included decreased
CD57 lymphocytes in patients with persistent
LB [88] and increased C3a and C4a at 96 h
following infection, i.e., during the acute
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disease stage [89]. Collectively, these cytokines
and chemokines generate a novel signature that
clearly distinguishes patients with acute LB
from normal controls [12]. These observations
were also noted in the mouse J774 macrophages
stimulated with live B. burgdorferi spirochetes
[76] and in whole blood cells from patients with
various clinical outcomes of LB [80]. This
analysis has permitted the description of a
cytokine signature associated with early stages
of infection and allowed for identification of
two distinctive cytokine profiles of two subsets
of patients who significantly diverged in
symptom presentation. The two subgroups
were either displaying elevated levels of
cytokines and chemokines during the early
disease stage or exhibiting levels of
inflammatory mediators that cluster around
those in normal controls [80]. This distinction
may be relevant to the host’s response to B.
burgdorferi infection and several PTLDS.
Furthermore, the detection of a subgroup of
LB patients who have low levels of immune
mediators could represent a set of
hyporesponsive subjects who can
immunologically clear the infection with
minimum inflammatory response [80].
POTENTIAL OF OMICS IN LYME
DISEASE: CONCLUSION
The use of the omics approach permits the
acquisition of large-scale data sets with the aim
of identifying biomarkers or biosignature of a
disease and/or elucidating functional or
pathological mechanisms [20, 21]. This high
throughput technology has been utilized
recently in LB and facilitated the
characterization of a distinctive disease
biosignature, particularly at the early disease
stages [12, 14, 70, 76]. The use of omics
techniques together with targeted marker
analysis have identified an array of gene
transcripts and a number of secreted
inflammatory mediators as candidates of a
refined biosignature or biomarkers for the
early recognition of LB [12, 14, 70, 76]. The
low sensitivity of serologic testing in the early
Fig. 4 Percentage of Lyme disease patients with modiﬁed
levels of inﬂammatory markers compared to healthy
controls [12]. Data were calculated as the percentage of
subjects above or below the average level of the given
inﬂammatory marker by determining the fold change in
each Lyme disease patient (n = 44) and healthy controls
(n = 23). Data were extrapolated by image analysis of the
heat map presenting the levels of immune mediators in the
original article [12]
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stages of LB is a consequence of the time it takes
to develop a humoral immune response
[90, 91]. In contrast, inflammation reflects the
instantaneous response of the innate immune
system to infection [12, 53, 54].
Omics studies facilitated the identification of
a range of cytokines and chemokines along the
innate immunity pathway for their role in the
onset and resolution of LB [12]. Specifically,
transcriptomic [70] and metabolomic [14]
analyses have uncovered multiple previously
undescribed pathways, genes, proteins and
metabolic factors that may be utilized in the
future as biomarkers for diagnosis and may
constitute prospective targets for new therapies.
Furthermore, analysis of the related chemokines
and cytokines in LB patients [12] permitted
identifying two subsets of patients with distinct
diseasephenotypeswhodiffer in symptoms, liver
involvement, lymphocyte levels and status of
seroconversion. These changes are involved in
disease pathogenesis and can be utilized to
develop disease markers. When integrated,
these findings may assist in developing specific
immunotherapeutic approaches in relation to
response to infection in addition to their
potential in diagnosis. However, although
levels of serum cytokines and chemokines may
be informative biomarkers for early LB stages,
some of these factors have a short serumhalf-life.
In fact, recent evidence for the instability of
certain inflammatory marker RNA species [92]
maypreclude theutility of these factors indisease
early detection. However, reliable diagnostic
testing using these biomarkers, particularly at
early disease stage, can still be employed if an
integrative approach is considered with a
number of long-term genomic, proteomic and/
or metabolomic biomarkers that can be
characterized at various diseases stages.
Technical advances in microarray, gene
expression analysis, mass spectrometry and
bioinformatics offer an exciting prospect for
future discovery of diagnostic and prognostic
markers in LB disease. The substantial
agreement between the information gathered
from the transcriptomics, proteomics and
metabolomics studies on the role of
inflammatory mediators in the early stages of
LB provides unprecedented opportunity to
develop a panel of biomarkers for diagnosis,
disease subtyping and response to therapy.
However, a number of propositions are
warranted for these prospects to advance,
particularly toward using inflammatory
markers as an LB diagnostic platform
deployable into clinical settings. Larger studies
with increased sampling resolution and various
LB disease stages are needed, perhaps through a
multinational collaborative effort that
encompasses various strains of Borrelia species.
This effort should be of a longitudinal nature to
evaluate gene, protein and metabolite
expressions and levels along the natural
history of the disease. Moreover, functional
studies are necessary to identify a specific set
of inflammatory genes or mediators that can be
employed in LB diagnosis. However, prior to
such a biosignature characterization, stringent
criteria should be introduced to ensure the most
robust biomarkers are identified and utilized.
Furthermore, variability in the assessment of
disease biosignature should be eliminated or
minimized, and establishing a system of
suitability protocols is an essential step in the
refinement and standardization of the
analytical procedures before their application
to a clinical setting. In parallel,
multidisciplinary teams and collaborative
efforts are necessary in view of the nature of
an omics approach. Omics techniques include
signal detection (microarray, mass spectra, etc.),
preprocessing (subtraction of background, peak
detection, analysis of expression, etc.), data
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normalization and identification of
differentially expressed molecules (genes,
peptides, metabolites, etc.) together with
powerful statistical and computational
techniques. All such competences need to be
assembled and directed to provide large-scale
discovery in the diagnosis of LB. Finally, a
comprehensive set of post-analysis data is yet to
be interrogated to facilitate a ‘‘one-stop’’
multidimensional biomarker discovery.
Integration of different omics platforms into a
single study population will allow a global
systemic approach to elucidate the
mechanisms of LB development and provide
novel tools for diagnosis and prognosis.
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